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Introduction
Acute myeloid leukemia (AML) is a malignant 
d i sorder  charac te r ized  by  c lona l  expans ion 
and accumulation of precursor myeloid cells with 
a reduced capacity to differentiate into more mature 
cellular elements. It can occur at all ages but has its peak 
incidence in the seventh decade. The heterogeneity of 
AML in terms of morphology, immunological phenotype, 
cytogenetic and molecular abnormalities is reflected in 
substantially different response to treatment between 
cases.
Treatment related mortality and resistance to standard 
chemotherapy are the two chief determinants of risks in 
AML (Estey, 2013). Diagnostic karyotype in AML predicts 
disease resistance and allows risk-stratified treatment 
approaches to be followed. Comprising of 11% of all cases, 
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Objectives: The heterogenous response to treatment in acute myeloid leukemia (AML) can be attributed largely to 
the difference in cytogenetic features identified in between cases. Cytogenetic analysis in acute leukemia is now 
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“AML with recurrent genetic abnormalities” is a separate 
entity recognized by 2008 World Health Organization 
(WHO) classification (Vardiman et al., 2009). This 
definition has been retained in updated 2016 classification 
as well (Arber et al., 2016). It is the most influential 
independent prognostic factors in terms of treatment 
outcomes (Grimwade and Hills, 2009).
Amongst various familiar cytogenetic abnormalities 
in AML, t (15;17) (q22;q12) in patients with acute 
promyelocytic leukemia (APL), t (8;21) (q22;q22) 
and inv (16) (p13q22)/t (16;16) (p13;q22) have been 
consistently found associated with better outcomes. 
Cure rates up to 60-70% have been documented in 
several assessments (Zhu et al., 2013). Conversely, 
abnormalities of 3q (abn(3q)), deletions of 5q (del(5q)), 
monosomies of chromosome 5 and/or 7 (-5/-7), t (9;22) or 
complex karyotype (more than three unrelated changes) are 
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associated with very poor prognoses. In fact, monosomal 
karyotype invariably portents resistant disease even after 
allogeneic bone marrow transplant (Kayser et al., 2012). 
The prognosis of normal karyotype, the commonest 
cytogenetic feature in AML, is highly variable ranging 
from cure to highly refractory disease. The influence of 
underlying mutations on outcome of such cases is well 
known (Schlenk et al., 2008).
The cytogenetic data of Pakistani adults with AML is 
scarce. Literature review retrieved a couple of small studies 
addressing the cytogenetic profile of Pakistani AML 
patients (Harani et al., 2006; Aziz and Qureshi, 2008). 
The current study aimed in determining the distribution of 
chromosomal abnormalities in Pakistani adult patients 
with AML in order to have an insight about the behavior of 
this condition.
Materials and Methods
Study area and subjects
This was a cross-sectional analysis performed at Aga 
Khan University Hospital in the Sections of Hematology 
and Molecular Pathology. Using non-probability 
consecutive sampling technique, all patients diagnosed 
as AML who were ≥15 years of age from January 2011 
to December 2016 were included in the analysis. Cases 
which didn’t yield metaphase chromosome were excluded 
from the analysis. 
Diagnosis
In all cases, the diagnosis of AML was confirmed 
by morphology and appropriate cytochemical staining. 
Immunophenotyping by either flow cytometry or 
immunohistochemistry was performed where possible by 
the use of standard methodologies. 
Cytogenetic analysis
Analysis was performed on pretreatment bone marrow 
samples by the use of conventional G-banding techniques. 
Bone marrow samples were cultured using standard 
culture techniques followed by harvesting (incubation, 
centrifugation and addition of hypotonic solution). After 
addition of fixative (3:1 methanol to glacial acetic acid) 
and trypsin treatment, Giemsa staining was performed. 
Slides were examined under microscope and at least 20 
mitosis were analyzed whenever possible. 
Cytogenetic abnormalities
Chromosomal abnormalities were identified and 
described according to the International System for Human 
Cytogenetic Nomenclature (ISCN 2009, 2013, 2016). 
Cytogenetic abnormalities were classified into balanced, 
unbalanced and complex abnormalities. Complex 
karyotype was defined as presence of three or more clonal 
chromosomal abnormalities in the absence of established 
chromosomal abnormalities. Based on WHO 2016 update, 
three cytogenetic risk groups were defined as favorable, 
intermediate and unfavorable (Arber et al., 2016).
Data analysis
Age, gender and types of cytogenetic abnormalities 
were included for analysis and results were expressed as 
frequencies and percentages. Categorical variables were 
compared by the use of the Chi-square test or Fisher Exact 
test. Significance of mean age between two groups was 
calculated by Independent-Samples T-Test. A p-value of 
<0.05 was taken as significant.
Ethical issues
An ethical exemption to conduct this analysis 
was granted by the institutional ethical review 
board (3569-Pat-ERC-15). Written and informed 
consent was taken from all patients as per institutional 
policy before collecting bone marrow samples. Relevant 
counseling regarding prognostic impact of the detected 
abnormality was provided to all who followed up in 
outpatient department or in the wards during admissions.
Results
A total of 321 adults were diagnosed with AML during 
the study period. There were 201 males and 120 females 
(M:F=1.7:1). Thirty-three (10%) cases didn’t yield 
metaphase chromosomes and were excluded from the 
analysis. Of successful 288 cases with cytogenetic results, 
a normal karyotype was identified in 176 (61.1%) patients 
and abnormal karyotype in 112 (38.9%) patients (Table 1). 
The most prevalent favorable chromosomal abnormality 
was t (8;21) (q22;q22), which was present in 24 (8.3%) of 
288 patients. Translocation (15;17) (q22:q12) occurred in 
14 (4.9%) and inv(16)(p13q22) was present in 2 (0.7%) 
patients. Poor cytogenetic abnormalities including t(6;9) 
(p23;q34), trisomy 8, monosomy 7 and complex karyotype 
collectively were identified in 38 (13.2%) patients 
(Table 1). Thirty four (11.8%) patients had miscellaneous 
chromosomal abnormalities including deletions, additions, 
inversions, other translocations and marker chromosomes. 
Forty-two percent (n=122) patients were under 30 years of 





t (8;21) (q22;q22.1) 24 (8.3)
t (15;17) (q22;q12) 14 (4.9)
inv (16) (p13.1q22) 2 (0.7)
t (6;9) (p23;q34.1) 2 (0.7)
Others 8 (2.8)
Unbalanced 36 (12.5)
Trisomy 8 7 (2.4)
Monosomy 7 3 (1)
Others 26 (9.0)
Complexƚ 26 (9)
Table 1. Karyotypic Features of 288 Patients with AML
Numbers and percentages presented are out of total cases with 
successful cytogenetic results; †Three or more clonal chromosomal 
abnormalities in the absence of aforementioned established 
chromosomal abnormalities
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were too infrequent to be analyzed separately.
Besides being the largest cytogenetic data in Pakistani 
adults with AML, other strength of this study is use 
of conventional cytogenetic method for karyotype 
determination. Conventional cytogenetic provides 
status of all chromosomes and hence, it identifies 
all the changes present in a karyotype. Nonetheless, 
a fraction of cases are liable to omission due to its 
inherent low sensitivity. More sophisticated methods 
like fluorescence in situ hybridization (FISH) and 
polymerase chain reaction (PCR) have higher yields 
but target only specific lesion in question and therefore, 
information about other possible findings is not provided. 
Next-Generation Sequencing (NGS) technology has 
made a huge impact on prognostication and clinical 
diagnostics. It has expanded genes that cause malignancies 
and will soon replace the routine testing for single gene 
mutation. This will play a significant role in personalized 
medicine. The 2016 WHO update emphasizes significant 
impact of AML biomarkers on patient outcome. 
Next-Generation Sequencing will serve as a powerful 
tool for gaining deeper insights into leukemia stem cell 
phenotype, signaling pathways and function. This will 
provide the basis for more comprehensive knowledge of 
data bank that can serve as a valuable tool to advance 
individualized treatment approaches including more 
accurate assessment of minimal residual disease in AML.
In conclusion, this study showed recurrent cytogenetic 
abnormalities in 14.6% Pakistani adults with AML. 
Favorable karyotypes, t(8;21)(q22;q22) followed by 
t (15;17) (q22:q12) were identified as the most prevalent 
specific chromosomal abnormalities; the cumulative 
prevalence however was not significantly different in 
various age groups. The complex karyotype constituted 
the predominant unfavorable karyotype. 
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